WA
NBIX icon

Whipplewood Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Whipplewood Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.36K Sell
14
-31
-69% -$4.6K ﹤0.01% 400
2026
Q1 		$5.93K Buy
+45
New +$5.97K ﹤0.01% 576
2025
Q3 		– Sell
-45
Closed -$5.66K – 864
2025
Q2 		$5.66K Buy
45
+44
+4,400% +$5.05K ﹤0.01% 670
2025
Q1 		$4.98K Sell
1
-44
-98% -$5.57K ﹤0.01% 699
2024
Q4 		$6.14K Buy
+45
New +$5.57K ﹤0.01% 649

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Whipplewood Advisors's NBIX Position: Q2 2026 in Review

Whipplewood Advisors reduced its Neurocrine Biosciences (NBIX) stake by 69% in Q2 2026, selling an estimated $4.6K and leaving 14 shares worth $2.36K. The position accounts for ﹤0.01% of the portfolio, ranked #400.

Whipplewood Advisors first reported a position in NBIX in Q4 2024 and has held it in 5 quarters since. The position peaked at $6.14K in Q4 2024. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Whipplewood Advisors held 14 shares of Neurocrine Biosciences worth $2.36K as of Q2 2026.
  • Whipplewood Advisors sold 31 Neurocrine Biosciences shares in Q2 2026, an estimated $4.6K.
  • Neurocrine Biosciences made up ﹤0.01% of Whipplewood Advisors's portfolio in Q2 2026, its #400 holding.
  • Whipplewood Advisors first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 5 quarters since.
  • Whipplewood Advisors's Neurocrine Biosciences position peaked at $6.14K in Q4 2024.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Whipplewood Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.